Talvey

Monotherapy for relapsed or refractory multiple myeloma in adults who have received at least 3 prior therapies including a proteasome inhibitor, immunomodulatory agent & anti-CD38 antibody, & have demonstrated disease progression on the last therapy.

SC Adult ≥18 yr Wkly dosing schedule: Step-up phase: 0.01 mg/kg on day 1; 0.06 mg/kg on day 3, may be administered between 2-4 days after the previous dose & may be given up to 7 days after the previous dose; 0.4 mg/kg on day 5, may be administered between 2-4 days after the previous dose & may be given up to 7 days after the previous dose. Treatment phase: 0.4 mg/kg wkly thereafter, maintain a min of 6 days between wkly doses. Biwkly dosing schedule: Step-up phase: 0.01 mg/kg on day 1; 0.06 mg/kg on day 3, may be administered between 2-4 days after the previous dose & may be given up to 7 days after the previous dose; 0.4 mg/kg on day 5, may be administered between 2-4 days after the previous dose & may be given up to 7 days after the previous dose; 0.8 mg/kg on day 7, may be administered between 2-4 days after the previous dose & may be given up to 7 days after the previous dose. Treatment phase: 0.8 mg/kg once every 2 wk thereafter, maintain a min of 12 days between biwkly doses.

Hypersensitivity.

Cancer Immunotherapy

L01FX29 - talquetamab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

POM